Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging

doi:10.1016/S1001-9294(11)60030-8

摘要/Abstract

关键词: hepatocellular carcinoma, radiotracer, positron emission tomography, biological behavior

Key words: hepatocellular carcinoma, radiotracer, positron emission tomography, biological behavior

Ting-ting He, and Jia-he Tian*. Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging[J].Chinese Medical Sciences Journal, 2011, 26(2): 113-118.

参考文献 64

1.	Delbeke D,Martin WH,Sandler MP,et al. Evaluation of benign vsmalignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510-6.
2.	Yun M, Bang SH, Kim JW, et al. Theimportance of acetyl coenzyme A synthetase for11C -acetate uptake and cell survival inhepatocellular carcinoma. J Nucl Med 2009; 50:1222-8.
3.	Park JW, Kim JH, Kim SK, et al. Aprospective evaluation of18F -FDGand11C -acetatePET/CT for detection of primary and metastatic hepatocellular carcinoma. J NuclMed 2008; 49:1912-21.
4.	Ho CL, Yu SC, Yeung DW.11C -acetate PET imaging inhepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-21.
5.	Yamamoto Y, Nishiyama Y, Kameyama R, et al. Detectionof hepatocellular carcinoma using11C -cholinePET: comparison with18F -FDGPET. J Nucl Med 2008; 49:1245-8.
6.	Warburg O,Posener K, Negelein E. On the metabolism of cancer cells. BiochemischeZeitschrift 1924; 152:319-44.
7.	Salem N, MacLennan GT, Kuang Y, et al.Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emissiontomography imaging on the woodchuck model of hepatocellular carcinoma withhistological correlation. Mol Imaging Biol 2007; 9:135-43.
8.	Trojan J, Schroeder O, Raedle J, et al. Fluorine-18FDGpositron emission tomography for imaging of hepatocellular carcinoma. Am JGastroenterol 1999; 94:3314-9.
9.	Torizuka T,Tamaki N,Inokuma T,et al. In vivo assessment of glucosemetabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-7.
10	Smeets P,Ham H, Ceelen W,et al. Differentiation between peri-anastomotic inflammatory changes and localrecurrence following neoadjuvant radiochemotherapy surgery for colorectalcancer using visual and semiquantitative analysis of PET-CT data. Q J Nucl Med Mol Imaging2010; 4:327-32.
11	Kong YH,Han CJ,Lee SD,et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose isuseful for predicting the prognosis of patients with hepatocellular carcinoma.Korean J Hepatol 2004; 10:279-87.
12	Hatano E,Ikai I, Higashi T, et al. Preoperativepositron emission tomography with fluorine-18-fluorodeoxyglu- cose ispredictive of prognosis in patients with hepatocellular carcinoma afterresection. World J Surg 2006; 30:1736-41.
13	Yang SH, Suh KS,Lee HW, et al. The role of 18F-FDG-PETimaging for the selection of liver transplantation candidates amonghepatocellular carcinoma patients. Liver Transpl 2006; 12:1655-60.
14	Wolfort RM, Papillion PW, Turnage RH, et al. Role ofFDG-PET in the evaluation and staging of hepatocellular carcinoma withcomparison of tumor size, AFP level, and histologic grade. Int Surg 2010;95:67-75.
15	Lee JW, Paeng JC, Kang KW, et al. Predictionof tumor recurrence by18F -FDGPET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682-7.
16	Higashi T, Hatano E, Ikai I, et al. FDG PET asa prognostic predictor in the early post-therapeutic evaluation forunresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82.
17	Kornberg A, Küpper B, Thrum K, et al. Increased18F -FDG uptake ofhepatocellular carcinoma on positron emission tomography independently predictstumor recurrence in liver transplant patients. Transplant Proc 2009; 41:2561- 3.
18	Kornberg A, Freesmeyer M, B?rthel E, et al.18F -FDG- uptake ofhepatocellular carcinoma on PET predicts microvascular tumor invasion in livertransplant patients. Am J Transpl2009; 9:592-600.
19	Ong LC, Jin Y, Song IC, et al. 2-[ 18F ]-2-deoxy-D-glucose (FDG)uptake in human tumor cells is related to the expression of GLUT-1 andhexokinase II. Acta Radiol 2008; 49:1145-53.
20	Paudyal B, Paudyal P, Oriuchi N, et al. Clinicalimplication of glucose transport and metabolism evaluated by18F -FDG PET in hepatocellularcarcinoma. Int J Oncol 2008; 33:1047-54.
21	Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathologicalpresentation of varying18F -FDGuptake and expression of glucose transporter 1 and hexokinase II in cases ofhepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 2008;22:83-6.
22	Ahn KJ, Hwang HS, Park JH, et al. Evaluationof the role of hexokinase type II in cellular proliferation and apoptosis usinghuman hepatocellular carcinoma cell lines. J Nucl Med 2009; 50:1525-32.
23	Zhao S, Kuge Y, Mochizuki T, et al.Biologic correlates of intratumoral heterogeneity in18F -FDG distribution with regionalexpression of glucose transporters and hexo- kinase-II in experimental tumor. JNucl Med 2005; 46:675-82.
24	Seo S, Hatano E, Higashi T, et al.P-glycoprotein expression affects18F -fluorodeoxyglucoseaccumulation in hepatocellular carcinoma invivo andin vitro. Int J Oncol2009; 34:1303-12.
25	Oyama N,Akino H, Kanamaru H, et al. 11 C-acetate PETimaging of prostate cancer. J Nucl Med 2002; 43:181-6.
26	YoshimotoM, Waki A, Yonekura Y, et al. Characterization of acetatemetabolism in tumor cells in relation to cell proliferation: acetate metabolismin tumor cells. Nucl Med Biol 2001; 28:117-22.
27	Vāvere AL,Kridel SJ,Wheeler FB,et al.1 -11C -acetateas a PET radiopharmaceutical for imaging fatty acid synthase expression inprostate cancer. J Nucl Med 2008; 49:327- 34.
29	Salem N, Kuang Y, Corn D, et al. [(Methyl)1- 11C ]-acetatemetabolism in hepatocellular carcinoma. Mol Imaging Biol 2011; 13:140-51.
30	Hwang KH, Choi DJ, Lee SY, et al. Evaluationof patients with hepatocellular carcinomas using [ 11C ]acetate and [ 18F ]FDG PET/CT: a preliminary study. Appl Radiat Isot 2009; 67:1195-8.
31	Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CTimaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;8:902-9.
32	Clarke DD.Fluoroacetate and fluorocitrate: mechanism of action. Neurochem Res 1991;16:1055-8.
33	Ponde DE, Dence CS, Oyama N, et al.18F -fluoroacetate: a potentialacetate analog for prostate tumor imaging-- invivo evaluation of18F -fluoroacetateversus11C -acetate.J Nucl Med 2007; 48:420-8.
34	Marik J, Ogasawara A, Martin-McNulty B, et al.PET of glial metabolism using 2 -18F -fluoroacetate.J Nucl Med 2009; 50:982-90.
35	Roivainen A, Forsback S, Gr?nroos T, et al. Blood metabolismof [methyl -11C ]choline; implicationsforin vivo imaging with positronemission tomography. Eur J Nucl Med 2000; 27:25-32.
36	Fallanca F, Giovacchini G, Picchio M, et al.Incidental detection by [ 11C ]cholinePET/CT of meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging2009; 53:417-21.
37	Kato T, Shinoda J, Nakayama N, et al.Metabolic assessment of gliomas using11C -methionine,[ 18F ]- fluorodeoxyglucose,and11C -cholinepositron-emission tomography. AJNR Am J Neuroradiol 2008; 29:1176-82.
38	Castellucci P,Fuccio C,Rubello D,et al. Is there a role for (11)C-choline PET/CT in the early detection ofmetastatic disease in surgically treated prostate cancer patients with a mildPSA increase 11C -methionine for differentiating tumors from granulomas in experimental ratmodels: a comparison with18F -FDGand18F -FLT. JNucl Med 2008; 49:135-41.
41	Rasey JS,Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure ofthymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
42	FrancisDL, Freeman A, Visvikis D, et al. In vivoimaging of cellular proliferation in colorectal cancer using positron emissiontomography. Gut 2003; 52:1602-6.
43	vanWestreenen HL, Cobben DC, Jager PL, et al. Comparison of18F -FLT PET and18F -FDG PET in esophagealcancer. J Nucl Med 2005; 46:400-4.
44	Smyczek-GargyaB, Fersis N, Dittmann H, et al. PET with [ 18F ]fluorothymidinefor imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging2004; 31:720-4.
45	Cobben DC, van der Laan BF, Maas B, et al.18F -FLT PET for visualization of laryngealcancer: comparison with18F -FDGPET. J Nucl Med 2004; 45:226-1.
46	Buck AK,Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors withPET:18F -FLT versus18F -FDG. J Nucl Med 2003; 44:1426-31.
47	VesselleH, Grierson J, Muzi M, et al. In vivovalidation of3’ deoxy -3’ -[ 18F ]fluorothymidine([ 18F ]FLT) as aproliferation imaging tracer in humans: correlation of [ 18F ]FLT uptake by positron emissiontomography with Ki-67 immunohistochemistry and flow cytometry in human lungtumors. Clin Cancer Res 2002; 8:3315-23.
48	Buck AK,Schirrmeister H, Hetzel M, et al. 3-deoxy- 3-[ 18F ]fluorothymidine-positron emissiontomography for noninvasive assessment of proliferation in pulmonary nodules.Cancer Res 2002; 62:3331-4.
49	Yap CS,Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with18F -fluorothymidine and18F -fluorodeoxyglucose-positron emissiontomography. Chest 2006; 129:393-401.
50	Eckel F, Herrmann K, Schmidt S, et al. Imagingof proliferation in hepatocellular carcinoma with the in vivo marker18F -fluorothymidine.J Nucl Med 2009; 50:1441-7.
51	Brizel DM,Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis ofcarcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-9.
52	Gagel B,Reinartz P,Demirel C,et al. [ 18F ] fluoromisonidazoleand [ 18F ] fluorodeoxyglucosepositron emission tomography in response evaluation after chemo-/ radiotherapyof non-small-cell lung cancer: a feasibility study. BMC Cancer2006; 6:51.
53	Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcomehypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.Int J Radiat Oncol Biol Phys 2001; 49:1171-82.
54	Rischin D,Hicks RJ, Fisher R, et al. Prognostic significance of [ 18F ]-misonidazole positron emission tomography-detectedtumor hypoxia in patients with advanced head and neck cancer randomly assignedto chemoradiation with or without tirapazamine: a substudy of Trans- TasmanRadiation Oncology Group Study 98.02. J Clin Oncol 2006; 24:2098-104.
55	Riedl CC,Brader P,Zanzonico P,et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis:a comparative study featuring dynamic18F -MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging2008; 35:39-46.
56	Ziemer LS, Evans SM, Kachur AV, et al.Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole18F -EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66.
57	Cai W, Chen K, Li ZB, et al.Dual-function probe for PET and near-infrared fluorescence imaging of tumorvasculature. J Nucl Med 2007; 48:1862-70.
58	Yan Y, Chen K, Yang M, et al. A new18F -labeled BBN-RGD peptideheterodimer with a symmetric linker for prostate cancer imaging. Amino Acids2010 Oct. [cited 2010 Oct 5]. Available from: http://www.springerlink.com/content/al642447583u8p 4l /
59	Zhao H, Wang JC, Sun QS, et al. RGD-basedstrategies for improving antitumor activity of paclitaxel-loaded liposomes innude mice xenografted with human ovarian cancer. J Drug Target 2009; 17:10-8.
60	Scheer MG,Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancerpatients with radiolabelled bevacizumab: lack of correlation with VEGF-Aexpression. Eur J Cancer 2008; 44:1835-40.
61	Schmidt K, Hoffend J, Altmann A, et al. TroponinI overexpression inhibits tumor growth, perfusion, and vascularization of morrishepatoma. J Nucl Med 2006; 47: 1506-14.
62	Kawamura K, Kubota K, Kobayashi T, et al.Evaluation of [ 11C ]SA5845and [ 11C ]SA4503 for imagingof sigma receptors in tumors by animal PET. Ann Nucl Med, 2005; 19:701-9.
63	Aloya R,Shirvan A, Grimberg H, et al. Molecular imaging of cell deathin vivo by a novel small moleculeprobe. Apoptosis 2006; 11:2089-101.
64	Toretsky J,Levenson A,Weinberg IN,et al. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceuticalfor imaging cell death. Nucl Med Biol 2004; 31: 747-52.

	*Corresponding author Tel: 86-10-66936429, Fax:86-10-68161853, E-mail: tianjh@vip.sina.com
	△Supported by National Natural ScienceFoundation of China (30770607).

[1]	Ye Jin, Li Zhou, Ke-min Jin, and Bao-cai Xing. Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells△[J]. Chinese Medical Sciences Journal, 2013, 28(1): 16-19.
[2]	Yao Zhang, Hua Zhang, Au Elizabeth, Xiao-qing Liu. Epidemiology of Hepatitis B and Associated Liver Diseases in China[J]. Chinese Medical Sciences Journal, 2012, 27(4): 243-248.

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心

Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging

Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 64

相关文章 2

Metrics

推荐阅读 10